Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 313
2013
-
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
Journal of Translational Medicine, year: 2013, volume: 11, edition: 77, DOI
-
Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
Year: 2013, type:
-
Cykliny D v regulaci a dysregulaci buněčného cyklu u mnohočetného myelomu
Klinická onkologie, year: 2013, volume: 26, edition: 5
-
Degradace proteinů ubikvitin-proteazomovou dráhou
Klinická onkologie, year: 2013, volume: 26, edition: 4
-
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Clinical lymphoma, myeloma & leukemia, year: 2013, volume: 13, edition: 2, DOI
-
Heterogeneity and Plasticity of Multiple Myeloma
Multiple Myeloma - A Quick Reflection on the Fast Progress, year: 2013, number of pages: 31 s.
-
Human Vdelta1 T cells represent a dominant gamma-delta T cell subset in patients with multiple myeloma
Year: 2013, type: Conference abstract
-
Inhibitory proteazomu v léčbě mnohočetného myelomu
Klinická onkologie, year: 2013, volume: 26, edition: 1
-
Molecular heterogeneity and centrosome-associated genes in multiple myeloma
Leukemia & Lymphoma, year: 2013, volume: 54, edition: 9, DOI
-
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma
BRITISH JOURNAL OF HAEMATOLOGY, year: 2013, volume: 163, edition: 5, DOI